Raw CMS121 Powder Basic Characters
|Product Name||CMS121 powder|
|Molecular Weight:||321.37 g/mol|
|Melting Point:||199 – 201 °C|
|Storage Temp:||Store at -20°C|
What is CMS121 powder?
CMS121 powder is a compound that acts as a fatty acid synthase inhibitor. Fatty acid synthase is an enzyme involved in the synthesis of fatty acids, which are essential components of cell membranes and play a role in various cellular processes. Inhibiting fatty acid synthase can impact lipid metabolism and have potential implications in diseases such as Alzheimer’s disease.
Additionally, CMS121 exhibits anti-inflammatory effects, which means it can help reduce inflammation in the body. Chronic inflammation is associated with several health conditions, including autoimmune diseases, cardiovascular diseases, and certain types of cancer. By reducing inflammation, CMS121 may have potential applications in the treatment of these inflammation-related conditions.
Another notable property of CMS121 is its antioxidative activity. Oxidative stress, caused by an imbalance between the production of reactive oxygen species (ROS) and the body’s antioxidant defense system, can lead to cellular damage and contribute to the development of various diseases, including neurodegenerative disorders and cardiovascular diseases.CMS121’s antioxidative activity enables it to counteract this oxidative stress, potentially protecting cells from damage.
Furthermore, CMS121 has shown renoprotective effects, indicating its ability to protect the kidneys from injury or dysfunction. Kidney diseases, such as chronic kidney disease or acute kidney injury, can have serious implications for overall health. By exerting renoprotective effects, CMS121 holds promise as a potential therapeutic agent for kidney-related conditions.
How does CMS121 work?
Alzheimer’s disease is a neurodegenerative disorder characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles in the brain. It is associated with cognitive decline, inflammation, and oxidative stress. The development of therapeutic strategies to target these pathological features is an active area of research.
In the context of Alzheimer’s disease, studies have investigated the potential benefits of fatty acid synthase inhibition using compounds like CMS121. Preclinical studies using transgenic mouse models of Alzheimer’s disease have shown that CMS121 can protect against excess lipid peroxidation, reduce inflammation, and alleviate cognitive loss.
Excess lipid peroxidation refers to the damage caused by reactive oxygen species to lipids in cell membranes. This process can lead to cellular dysfunction and contribute to the progression of neurodegenerative diseases. By inhibiting fatty acid synthase, CMS121 may help restore lipid homeostasis and reduce lipid peroxidation.
Furthermore, inflammation is known to play a significant role in the progression of Alzheimer’s disease. Inflammatory processes in the brain can contribute to neuronal damage and cognitive decline. Studies have indicated that CMS121 has anti-inflammatory effects, which could be beneficial in mitigating the inflammatory response associated with Alzheimer’s disease.
The Benefits of CMS121 powder
CMS121 powder is a substituted quinoline compound that possesses several beneficial properties. It has been found to exhibit neuroprotective, anti-inflammatory, antioxidative, and renoprotective activities. Here are some specific effects and actions of CMS121:
Neuroprotection: CMS121 has been shown to protect HT22 mouse hippocampal cells from glutamate-induced damage in vitro.It helps maintain the levels of glutathione (GSH), an important antioxidant, in these cells. Additionally, CMS121 demonstrates protection against ischemia and oxytocin (glutamate-induced cell death) in HT22 cells.
Anti-inflammatory: CMS121 exhibits anti-inflammatory effects by preventing the activation of N9 microglia, a type of immune cell in the brain. In the presence of lipopolysaccharide (LPS), CMS121 reduces microglial activation by 82% in N9 microglia. This anti-inflammatory property can be beneficial in various neuroinflammatory conditions.
Antioxidant: CMS121 scavenges free radicals, as demonstrated in a Trolox equivalent activity concentration (TEAC) assay. Free radicals are highly reactive molecules that can cause cellular damage and contribute to various diseases. By scavenging free radicals, CMS121 acts as an antioxidant and helps protect cells from oxidative stress.
Induction of differentiation: CMS121 induces the differentiation of PC12 cells.PC12 cells are often used as a model system for studying neuronal differentiation and function. The ability of CMS121 to induce differentiation in these cells suggests its potential role in promoting neuronal development and repair.
Renoprotection: CMS121 exhibits renoprotective effects, particularly in a SAMP8 mouse model of chronic kidney disease associated with rapid aging. When administered at a dose of 10 mg/kg per day starting at nine months of age, CMS121 reduces kidney weight loss and decreases the expression of TNF-α,caspase-1, and inducible nitric oxide synthase (iNOS). These effects indicate a potential therapeutic role for CMS121 in protecting the kidneys from damage associated with chronic kidney disease.
In summary, CMS121 is a promising compound with multiple beneficial properties, including neuroprotection, anti-inflammatory effects, antioxidative activity, and renoprotection. Its diverse actions make it a potential candidate for the treatment of various neurological disorders,inflammation-related conditions, and kidney diseases.
Where to buy CMS121 powder?
AASraw is the best place to buy CMS121 wholesale. All of our products come with an independent,third-party-issued Certificate of Analysis for identification, purity, and concentration. And we have bulk CMS121 for sale in stock!
AASraw is a CMS121 supplier and CMS121 manufacturer which has an independent lab and a large factory as support, all production will be carried out under CGMP regulation and a trackable quality control system. The CMS121 supply system is stable, and both retail and wholesale orders are acceptable. If you want to buy CMS121 online, welcome to visit our website(aasraw.com).
CMS121 Testing Report-HNMR
What is HNMR and What does HNMR spectrum tell you? H Nuclear Magnetic Resonance (NMR) spectroscopy is an analytical chemistry technique used in quality control and research for determining the content and purity of a sample as well as its molecular structure. For example, NMR can quantitatively analyze mixtures containing known compounds. For unknown compounds, NMR can either be used to match against spectral libraries or to infer the basic structure directly. Once the basic structure is known, NMR can be used to determine molecular conformation in solution as well as studying physical properties at the molecular level such as conformational exchange, phase changes, solubility, and diffusion.
How to buy CMS121 from AASraw?
❶To contact us by our email inquiry system, or leave your WhatsApp number to us, our customer service representative(CSR) will contact you in 12 hours.
❷To provide us with your inquired quantity and address.
❸Our CSR will provide you with the quotation, payment term, tracking number, delivery ways, and estimated arrival date(ETA).
❹Payment done and the goods will be sent out in 12 hours.
❺Goods received and give comments.
 Schneider L.S.,Mangialasche F.,Andreasen N.,Feldman H.,Giacobini E.,Jones R.Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014.J.Intern.Med.2014;275: 251–283.doi: 10.1111/joim.12191.
 Ashraf A.,Jeandriens J.,Parkes H.G.,So P.-W.Iron dyshomeostasis,lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis.Redox Biol.2020;32: 101494.doi: 10.1016/J.REDOX.2020.101494.
 Trares K.,Gào X.,Perna L.,Rujescu D.,Stocker H.,Möllers T.Associations of urinary 8-iso-prostaglandin F2α levels with all-cause dementia,Alzheimer’s disease,and vascular dementia incidence: results from a prospective cohort study.Alzheimers Dement.2020;16(5): 804–813.doi: 10.1002/alz.12081.